332 related articles for article (PubMed ID: 19843843)
1. Distinct microRNA alterations characterize high- and low-grade bladder cancer.
Catto JW; Miah S; Owen HC; Bryant H; Myers K; Dudziec E; Larré S; Milo M; Rehman I; Rosario DJ; Di Martino E; Knowles MA; Meuth M; Harris AL; Hamdy FC
Cancer Res; 2009 Nov; 69(21):8472-81. PubMed ID: 19843843
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer.
Drayton RM; Peter S; Myers K; Miah S; Dudziec E; Bryant HE; Catto JW
Oncotarget; 2014 Aug; 5(15):6375-86. PubMed ID: 25071007
[TBL] [Abstract][Full Text] [Related]
3. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Gui Y; Cai Z
J Surg Oncol; 2013 Feb; 107(2):201-5. PubMed ID: 22766726
[TBL] [Abstract][Full Text] [Related]
4. Predicting progression of bladder urothelial carcinoma using microRNA expression.
Rosenberg E; Baniel J; Spector Y; Faerman A; Meiri E; Aharonov R; Margel D; Goren Y; Nativ O
BJU Int; 2013 Nov; 112(7):1027-34. PubMed ID: 23387295
[TBL] [Abstract][Full Text] [Related]
5. The relation between Ring Box-1 protein overexpression and tumor grade and stage in bladder urothelial cell carcinoma.
Celik ZE; Kaynar M; Karabagli P; Gergerlioglu N; Goktas S
Cancer Biomark; 2017 Dec; 20(4):389-394. PubMed ID: 28946546
[TBL] [Abstract][Full Text] [Related]
6. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
7. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
8. Higher Expression of miR-182 in Cytology Specimens of High-Grade Urothelial Cell Carcinoma: A Potential Diagnostic Marker.
Wei S; Bing Z; Yao Y; Master SR; Gupta P
Acta Cytol; 2015; 59(1):109-12. PubMed ID: 25676538
[TBL] [Abstract][Full Text] [Related]
9. EIF2C, Dicer, and Drosha are up-regulated along tumor progression and associated with poor prognosis in bladder carcinoma.
Zhang Z; Zhang G; Kong C; Bi J; Gong D; Yu X; Shi D; Zhan B; Ye P
Tumour Biol; 2015 Jul; 36(7):5071-9. PubMed ID: 25656609
[TBL] [Abstract][Full Text] [Related]
10. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
[TBL] [Abstract][Full Text] [Related]
11. WISP1 genetic variants as predictors of tumor development with urothelial cell carcinoma.
Lee HL; Chiou HL; Wang SS; Hung SC; Chou MC; Yang SF; Hsieh MJ; Chou YE
Urol Oncol; 2018 Apr; 36(4):160.e15-160.e21. PubMed ID: 29277583
[TBL] [Abstract][Full Text] [Related]
12.
Kacew A; Sweis RF
Front Immunol; 2020; 11():575258. PubMed ID: 33224141
[No Abstract] [Full Text] [Related]
13. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
14. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Burger M; van der Aa MN; van Oers JM; Brinkmann A; van der Kwast TH; Steyerberg EC; Stoehr R; Kirkels WJ; Denzinger S; Wild PJ; Wieland WF; Hofstaedter F; Hartmann A; Zwarthoff EC
Eur Urol; 2008 Oct; 54(4):835-43. PubMed ID: 18166262
[TBL] [Abstract][Full Text] [Related]
15. The evolving understanding of microRNA in bladder cancer.
Guancial EA; Bellmunt J; Yeh S; Rosenberg JE; Berman DM
Urol Oncol; 2014 Jan; 32(1):41.e31-40. PubMed ID: 23911686
[TBL] [Abstract][Full Text] [Related]
16. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
17. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Dicer, a component of the microRNA machinery, in bladder cancer.
Wu D; Tao J; Xu B; Li P; Lu Q; Zhang W
Mol Med Rep; 2012 Mar; 5(3):695-9. PubMed ID: 22179432
[TBL] [Abstract][Full Text] [Related]
20. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
Balbás-Martínez C; Rodríguez-Pinilla M; Casanova A; Domínguez O; Pisano DG; Gómez G; Lloreta J; Lorente JA; Malats N; Real FX
PLoS One; 2013; 8(5):e62483. PubMed ID: 23650517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
